1 |
Untersuchung der Kinetik der Wirkung von Clindamycin gegen Plasmodium falciparum in vitroBurkhardt, Christian Dominik, January 2007 (has links)
Tübingen, Univ., Diss., 2007.
|
2 |
Clindamycin Therapy for Chlamydia Trachomatis in WomenCampbell, William F., Dodson, Melvin G. 01 January 1990 (has links)
The population for this study consisted of 4013 sexually active women seen for family planning. Culture for Chlamydia trachomatis yielded an isolation rate of 6.1%. Women aged 16 to 25 accounted for 81.7% of the C. trachomatis infections, while those younger than 16 or older than 35 accounted for only 2.4% of the infections. Of the 246 patients whose cultures were positive for C. trachomatis, 159 (65%) were asymptomatic. The incidence of C. trachomatis was 11.2% among those with symptoms but only 6.4% among the asymptomatic group. Among 63 patients with Neisseria gonorrhoeae (who were excluded from the study), 26 (41.3%) also were infected by C. trachomatis. There were no microbiologic drug failures with erythromycin or clindamycin. Of 56 patients who enrolled in the clindamycin arm of the protocol, 48 (85.7%) completed therapy and experienced microbiologic and clinical cures. In contrast, erythromycin therapy was completed by only 25 of 57 women (43.9%) enrolled. The number of side effect failures for erythromycin was 22 of 57 (38.6%). This was more than five times the number of side effect failures for clindamycin (4 of 56, or 7.1%).
|
3 |
Antibiotic-resistant acne: lessons from EuropeSnelling, Anna M., Coates, Philip D., Cove, J.H., Ross, Jeremy I. 20 July 2009 (has links)
No / Background Propionibacterium acnes and P. granulosum are widely regarded as the aetiological agents of inflammatory acne. Their proliferation and metabolism are controlled using lengthy courses of oral and/or topical antibiotics. Despite numerous reports of skin colonization by antibiotic-resistant propionibacteria among acne patients, accurate prevalence data are available only for the U.K.
Objectives To determine the prevalence of skin colonization by antibiotic-resistant propionibacteria among acne patients and their contacts from six European centres.
Methods Skin swabs were collected from 664 acne patients attending centres in the U.K., Spain, Italy, Greece, Sweden and Hungary. Phenotypes of antibiotic-resistant propionibacteria were determined by measuring the minimum inhibitory concentrations (MIC) of a panel of tetracycline and macrolide, lincosamide and streptogramin B (MLS) antibiotics. Resistance determinants were characterized by polymerase chain reaction (PCR) using primers specific for rRNA genes and erm(X), followed by nucleotide sequencing of the amplified DNA.
Results Viable propionibacteria were recovered from 622 patients. A total of 515 representative antibiotic-resistant isolates and 71 susceptible isolates to act as control strains were characterized phenotypically. The prevalence of carriage of isolates resistant to at least one antibiotic was lowest in Hungary (51%) and highest in Spain (94%). Combined resistance to clindamycin and erythromycin was much more common (highest prevalence 91% in Spain) than resistance to the tetracyclines (highest prevalence 26·4% in the U.K.). No isolates resistant to tetracycline were detected in Italy, or in Hungary. Overall, there were strong correlations with prescribing patterns. Prevalence of resistant propionibacteria on the skin of untreated contacts of the patients varied from 41% in Hungary to 86% in Spain. Of the dermatologists, 25 of 39 were colonized with resistant propionibacteria, including all those who specialized in treating acne. None of 27 physicians working in other outpatient departments harboured resistant propionibacteria.
Conclusions The widespread use of topical formulations of erythromycin and clindamycin to treat acne has resulted in significant dissemination of cross-resistant strains of propionibacteria. Resistance rates to the orally administered tetracycline group of antibiotics were low, except in Sweden and the U.K. Resistant genotypes originally identified in the U.K. are distributed widely throughout Europe. Antibiotic-resistant propionibacteria should be considered transmissible between acne-prone individuals, and dermatologists should use stricter cross-infection control measures when assessing acne in the clinic.
Background Propionibacterium acnes and P. granulosum are widely regarded as the aetiological agents of inflammatory acne. Their proliferation and metabolism are controlled using lengthy courses of oral and/or topical antibiotics. Despite numerous reports of skin colonization by antibiotic-resistant propionibacteria among acne patients, accurate prevalence data are available only for the U.K.
Objectives To determine the prevalence of skin colonization by antibiotic-resistant propionibacteria among acne patients and their contacts from six European centres.
Methods Skin swabs were collected from 664 acne patients attending centres in the U.K., Spain, Italy, Greece, Sweden and Hungary. Phenotypes of antibiotic-resistant propionibacteria were determined by measuring the minimum inhibitory concentrations (MIC) of a panel of tetracycline and macrolide, lincosamide and streptogramin B (MLS) antibiotics. Resistance determinants were characterized by polymerase chain reaction (PCR) using primers specific for rRNA genes and erm(X), followed by nucleotide sequencing of the amplified DNA.
Results Viable propionibacteria were recovered from 622 patients. A total of 515 representative antibiotic-resistant isolates and 71 susceptible isolates to act as control strains were characterized phenotypically. The prevalence of carriage of isolates resistant to at least one antibiotic was lowest in Hungary (51%) and highest in Spain (94%). Combined resistance to clindamycin and erythromycin was much more common (highest prevalence 91% in Spain) than resistance to the tetracyclines (highest prevalence 26·4% in the U.K.). No isolates resistant to tetracycline were detected in Italy, or in Hungary. Overall, there were strong correlations with prescribing patterns. Prevalence of resistant propionibacteria on the skin of untreated contacts of the patients varied from 41% in Hungary to 86% in Spain. Of the dermatologists, 25 of 39 were colonized with resistant propionibacteria, including all those who specialized in treating acne. None of 27 physicians working in other outpatient departments harboured resistant propionibacteria.
Conclusions The widespread use of topical formulations of erythromycin and clindamycin to treat acne has resulted in significant dissemination of cross-resistant strains of propionibacteria. Resistance rates to the orally administered tetracycline group of antibiotics were low, except in Sweden and the U.K. Resistant genotypes originally identified in the U.K. are distributed widely throughout Europe. Antibiotic-resistant propionibacteria should be considered transmissible between acne-prone individuals, and dermatologists should use stricter cross-infection control measures when assessing acne in the clinic.
Background Propionibacterium acnes and P. granulosum are widely regarded as the aetiological agents of inflammatory acne. Their proliferation and metabolism are controlled using lengthy courses of oral and/or topical antibiotics. Despite numerous reports of skin colonization by antibiotic-resistant propionibacteria among acne patients, accurate prevalence data are available only for the U.K.
Objectives To determine the prevalence of skin colonization by antibiotic-resistant propionibacteria among acne patients and their contacts from six European centres.
Methods Skin swabs were collected from 664 acne patients attending centres in the U.K., Spain, Italy, Greece, Sweden and Hungary. Phenotypes of antibiotic-resistant propionibacteria were determined by measuring the minimum inhibitory concentrations (MIC) of a panel of tetracycline and macrolide, lincosamide and streptogramin B (MLS) antibiotics. Resistance determinants were characterized by polymerase chain reaction (PCR) using primers specific for rRNA genes and erm(X), followed by nucleotide sequencing of the amplified DNA.
Results Viable propionibacteria were recovered from 622 patients. A total of 515 representative antibiotic-resistant isolates and 71 susceptible isolates to act as control strains were characterized phenotypically. The prevalence of carriage of isolates resistant to at least one antibiotic was lowest in Hungary (51%) and highest in Spain (94%). Combined resistance to clindamycin and erythromycin was much more common (highest prevalence 91% in Spain) than resistance to the tetracyclines (highest prevalence 26·4% in the U.K.). No isolates resistant to tetracycline were detected in Italy, or in Hungary. Overall, there were strong correlations with prescribing patterns. Prevalence of resistant propionibacteria on the skin of untreated contacts of the patients varied from 41% in Hungary to 86% in Spain. Of the dermatologists, 25 of 39 were colonized with resistant propionibacteria, including all those who specialized in treating acne. None of 27 physicians working in other outpatient departments harboured resistant propionibacteria.
Conclusions The widespread use of topical formulations of erythromycin and clindamycin to treat acne has resulted in significant dissemination of cross-resistant strains of propionibacteria. Resistance rates to the orally administered tetracycline group of antibiotics were low, except in Sweden and the U.K. Resistant genotypes originally identified in the U.K. are distributed widely throughout Europe. Antibiotic-resistant propionibacteria should be considered transmissible between acne-prone individuals, and dermatologists should use stricter cross-infection control measures when assessing acne in the clinic.
|
4 |
Detection of a new erm(X)-mediated antibiotic resistance in Egyptian cutaneous propionibacteriaEl-Mahdy, Taghrid S., Abdalla, S., El-Domany, R., Mohamed, M.S., Ross, Jeremy I., Snelling, Anna M. January 2010 (has links)
No / A total of 107 antibiotic-resistant propionibacteria were isolated from the face of 102 Egyptian acne patients, dermatology staff and controls. Erythromycin-clindamycin-resistant propionibacteria were chosen to detect erm(X) gene and it was detected in 29 of 107 (27%) strains. However, just 7 strains had IS1249I, 3 of them had also Tn5432. The erm(X) gene which is not carried on Tn5432 confers inducible resistance to telithromycin by erythromycin or clindamycin. The DNA sequences of the PCR amplification products of this new erm(X)-mediated antibiotic resistance showed >99% identity to the erm(X) gene isolated from a Corynebacterium jeikeium. Southern blotting analysis of the erm(X)-specific probe shows that there were two copies of this resistance gene integrated within the chromosomal DNA. This is the first report of erm(X) being carried by Propionibacterium acnes outside Europe. Whilst the gene is associated with Tn5432 in some strains, the data suggests other genetic element carrying erm(X). The high carriage of erm(X) may affect the efficacy of clindamycin and macrolides for acne treatment in Egypt. / Egyptian Ministry of Higher Education
|
5 |
Bestimmung der in vitro Aktivität von Clindamycin, Imipenem, Metronidazol und Piperacillin/Tazobactam gegenüber sensiblen und resistenten Bacteroides fragilis Stämmen mittels AbsterbekinetikFunke, Matthias 23 December 2014 (has links) (PDF)
Obligat anaerob wachsende Bakterien sind an einer Vielzahl von Infektionen beteiligt. Dabei ist Bacteroides fragilis einer der wichtigsten opportunistischen Erreger unter den Anaerobiern. Bei Verdacht auf eine Infektion durch obligate Anaerobier muss nach Materialentnahme für die mikrobiologische Diagnostik unverzüglich eine kalkulierte Therapie eingeleitet werden. Oft ist eine chirurgische Therapie notwendig, die ebenso wie eine adäquate Antibiotikatherapie entscheidend für den Verlauf der Erkrankung ist.
Wichtige Substanzen für eine Therapie bei Infektionen mit Beteiligung von B. fragilis sind Clindamycin, Imipenem, Metronidazol und Piperacillin/Tazobactam. Um Aussagen zur in vitro Wirksamkeit dieser Antibiotika gegenüber obligaten Anaerobiern treffen zu können, wurden in der vorliegenden Arbeit die Aktivitäten von verschiedenen Konzentrationen des jeweiligen Antibiotikums auf das Wachstum von sensiblen und resistenten B. fragilis Stämmen mittels Absterbekinetik untersucht. In Abhängigkeit von der zuvor ermittelten minimalen Hemmkonzentration des jeweiligen Antibiotikums wurden die Stämme in 2 Gruppen eingeteilt. Die erste Gruppe umfasst alle Stämme mit einer MHK ≤ 8 µg/ml. In der zweiten Gruppe sind die Stämme mit einer MHK > 8 µg/ml zusammengefasst. Die einzelnen Stämme wurden mit einem Vielfachen der minimalen Hemmkonzentration (MHK) beziehungsweise einem Vielfachen der im menschlichen Blutplasma maximal erreichbaren Konzentration (Cmax) des jeweiligen Antibiotikums inkubiert und die Bakterienkonzentration zu definierten Zeitpunkten ermittelt. Dadurch können sowohl die Wirksamkeit unterschiedlicher Antibiotikakonzentrationen als auch verschiedene Antibiotikaklassen miteinander verglichen und Aussagen zu Empfehlungen für kalkulierte Therapien getroffen werden.
|
6 |
Bestimmung der in vitro Aktivität von Clindamycin, Imipenem, Metronidazol und Piperacillin/Tazobactam gegenüber sensiblen und resistenten Bacteroides fragilis Stämmen mittels AbsterbekinetikFunke, Matthias 04 December 2014 (has links)
Obligat anaerob wachsende Bakterien sind an einer Vielzahl von Infektionen beteiligt. Dabei ist Bacteroides fragilis einer der wichtigsten opportunistischen Erreger unter den Anaerobiern. Bei Verdacht auf eine Infektion durch obligate Anaerobier muss nach Materialentnahme für die mikrobiologische Diagnostik unverzüglich eine kalkulierte Therapie eingeleitet werden. Oft ist eine chirurgische Therapie notwendig, die ebenso wie eine adäquate Antibiotikatherapie entscheidend für den Verlauf der Erkrankung ist.
Wichtige Substanzen für eine Therapie bei Infektionen mit Beteiligung von B. fragilis sind Clindamycin, Imipenem, Metronidazol und Piperacillin/Tazobactam. Um Aussagen zur in vitro Wirksamkeit dieser Antibiotika gegenüber obligaten Anaerobiern treffen zu können, wurden in der vorliegenden Arbeit die Aktivitäten von verschiedenen Konzentrationen des jeweiligen Antibiotikums auf das Wachstum von sensiblen und resistenten B. fragilis Stämmen mittels Absterbekinetik untersucht. In Abhängigkeit von der zuvor ermittelten minimalen Hemmkonzentration des jeweiligen Antibiotikums wurden die Stämme in 2 Gruppen eingeteilt. Die erste Gruppe umfasst alle Stämme mit einer MHK ≤ 8 µg/ml. In der zweiten Gruppe sind die Stämme mit einer MHK > 8 µg/ml zusammengefasst. Die einzelnen Stämme wurden mit einem Vielfachen der minimalen Hemmkonzentration (MHK) beziehungsweise einem Vielfachen der im menschlichen Blutplasma maximal erreichbaren Konzentration (Cmax) des jeweiligen Antibiotikums inkubiert und die Bakterienkonzentration zu definierten Zeitpunkten ermittelt. Dadurch können sowohl die Wirksamkeit unterschiedlicher Antibiotikakonzentrationen als auch verschiedene Antibiotikaklassen miteinander verglichen und Aussagen zu Empfehlungen für kalkulierte Therapien getroffen werden.
|
7 |
Μηχανισμός δράσεως της κλινδαμυκίνης στην πρωτεινική σύνθεση : επίδραση των πολυαμινώνΚούβελα, Αικατερίνη 28 June 2007 (has links)
Η κλινδαμυκίνη αποτελεί μέλος της οικογενείας των MLS αντιβιοτικών, με ευρύτατες εφαρμογές στην Ιατρική. Προσδεδενόμενη στο κέντρο της πεπτιδυλοτρανσφεράσης, δρα ως αναστολέας της πρωτεϊνικής σύνθεσης. Η ακριβής θέση δράσης της δεν έχει πλήρως διασαφηνισθεί. Διάφορες μελέτες έχουν δείξει πως δρα στην Α θέση, ενώ άλλες στην Ρ θέση της μεγάλης ριβοσωματικής υπομονάδας. Στην παρούσα εργασία γίνεται λεπτομερής κινητική ανάλυση της αναστολής του σχηματισμού του πεπτιδικού δεσμού από την κλινδαμυκίνη σε ιοντικό περιβάλλον που πλησιάζει το φυσιολογικό του κυττάρου (4,5 mM Mg2+, 150 mM NH4+). Συγκεκριμένα, η δράση της κλινδαμυκίνης μελετήθηκε σε ένα σύστημα ελεύθερο-κυττάρων του εντεροβακτηρίου Escherichia coli, όπου ένας πεπτιδικός δεσμός σχηματίζεται μεταξύ πουρομυκίνης και AcPhe-tRNA, προσδεδενόμενου στην Ρ-θέση ριβοσωμάτων προγραμματισμένων με poly(U). Η πουρομυκίνη δρα ως ανάλογο του 3΄ άκρου ενός αμινοακυλο-tRNA ενώ το τριμερές AcPhe-tRNA∙ poly(U)∙ ριβόσωμα, σύμπλοκο C, ως ανάλογο του εναρκτήριου μεταφραστικού συμπλόκου. Η κινητική ανάλυση αποκάλυψε ότι η κλινδαμυκίνη συμπεριφέρεται ως αναστολέας βραδείας δεσμεύσεως. Μετά από μια παροδική αλληλεπίδραση με την Α-θέση, εγκαθίσταται κοντά στην Ρ-θέση του ριβοσώματος με αποτέλεσμα να επηρεάζει την ταχύτητα σχηματισμού του πεπτιδικού δεσμού. Στην συνέχεια μελετήθηκε η επίδραση των πολυαμινών στην αλληλεπίδραση της κλινδαμυκίνης με το σύμπλοκο C. Τα αποτελέσματα έδειξαν πως η σπερμίνη παρεμποδίζει την επίδραση της κλινδαμυκίνης στην Ρ-θέση, όμως επηρεάζει ευνοϊκά και σε μεγαλύτερο βαθμό, την αρχική δέσμευση του φαρμάκου στην Α-θέση ελαττώνοντας το εντροπικό κόστος. Η επίδραση αυτή δεν μεταβλήθηκε όταν αντί της σπερμίνης χρησιμοποιήθηκαν ριβοσώματα επισημασμένα μ’ένα φωτοδραστικό ανάλογο της σπερμίνης, την Ν1-αζιδοβενζαμιδινο-σπερμίνη, ή όταν στο διάλυμα επώασης προστέθηκε μείγμα σπερμίνης και σπερμιδίνης. Πειράματα σταυρο-σύνδεσης έδειξαν ότι η σπερμίνη προσδένεται πλησίον της θέσης δέσμευσης της κλινδαμυκίνης. Η παρατήρηση αυτή οδήγησε στην υπόθεση, ότι οι πολυαμίνες δεσμευόμενες πλησίον της θέσης πρόσδεσης της κλινδαμυκίνης επηρεάζουν την αλληλεπίδραση του αντιβιοτικού με το ριβόσωμα, επάγοντας αλλαγές διαμόρφωσης στο ριβοσωμικό σύμπλοκο. Η υπόθεση αυτή βρίσκεται σε συμφωνία με πειράματα χημικής προστασίας, που έδειξαν, ότι οι πολυαμίνες επηρεάζουν σημαντικά την τριτοταγή δομή του ριβοσώματος. Από άποψη φαρμακευτικών εφαρμογών η παρούσα μελέτη εισηγείται ότι, κάθε φορά που ένα αντιβιοτικό, με μοριακό στόχο το ριβόσωμα, είναι προς σχεδιασμό, η επίδραση του ιοντικού περιβάλλοντος πρέπει να λαμβάνεται σοβαρά υπόψη. / Clindamycin is a representative antibiotic of the MLS family, widely used in clinical practice. It inhibits protein synthesis by binding to the peptidyltransferase center of the ribosome. Clindamycin’s exact site of action is not known. Several studies have shown that it is an inhibitor of the A-site. However, there are also stydies that suggest that clindamycin acts at the P-site of the large ribosomal subunit. In this study, we re-examined the mechanism by which the antibiotic inhibits the formation of peptide bond in an ionic environment that resembles in vivo conditions (4.5 mM Mg2+, 150 mM NH4+). Clindamycin was investigated in a cell-free system derived from Escherichia coli, in which a peptide bond is formed between puromycin and AcPhe-tRNA bound at the P-site of poly (U) –programmed ribosomes. Puromycin can be considered as an analogue of the 3’-end of aminoacyl-tRNA, while the ternary complex AcPhe-tRNA∙poly(U)∙ ribosome (complex C) as an analogue of the initiation translation complex. Kinetics revealed that clindamycin behaves as a slow – binding inhibitor. After a transient interaction with the A-site of ribosomes, it slowly accommodates near the P-site so that peptide bond is still formed but with a lower velocity. Next, we investigated the influence of polyamines to the interaction of clindamycin with complex C. It was found that spermine hinders the accommodation of clindamycin to the P-site, but exerts a beneficial, more pronounced, effect on the potency of the drug by lowering the entropic cost of clindamycin binding to the A-site. Polyamine effect was not substantially altered when ribosomes labeled with a photoreactive analogue of spermine, N1-azidobenzamidino-spermine, were used or when a mixture of spermine and spermidine was added in the incubation mixture, instead of spermine alone. Cross-linking experiments have demonstrated that spermine binds to the vicinity of the antibiotic binding pocket. This observation temped us to suppose that polyamines bound adjacently to the binding site of clindamycin modulate the interaction of this drug with the ribosome by inducing conformational changes in the elongating ribosomal complex. Such a hypothesis is in agreement with chemical protection data revealing that polyamines influence significantly the tertiary structure of ribosomes. From the stand point of pharmaceutical applications, the present work postulates that when a drug is designed to target to the ribosome, the influence of the ionic environment should be taken into account.
|
8 |
Bacterial Vaginosis : Diagnosis, Prevalence, and TreatmentEriksson, Katarina January 2011 (has links)
Bacterial Vaginosis (BV) is a disorder of unknown etiology, characterized by a foul smelling vaginal discharge, loss or reduction of the normal vaginal Lactobacilli, and overgrowth of other anaerobic bacteria. Thus, it presents a formidable problem for clinicians as well as microbiologists researching its etiology, clinical course, treatment, and epidemiology. The present work focuses on the unresolved issues of the epidemiology and treatment of BV in order to provide valid methods for treatment studies of this condition and to describe the prevalence of BV in defined populations. The first study validates the use of PAP-stained smears in the diagnosis of BV. The study assesses the methods of Amsel’s clinical criteria and Nugent criteria on Gram-stain smears, against Pap-stained smears and also validates different observers. The result shows that the PAP-staining of vaginal smears is a good method in BV diagnosis; the kappa value is 0.86 (interobserver weighted kappa index) compared to 0.81 for Gram-stained smears, and 0.70 for rehydrated air-dried smears using the mean Nugent score as the criterion standard. This enables population based studies on archived PAP-stained smears from the screening of cervical cancer. In the second study, we use the knowledge gained from study one to investigate the prevalence of BV in a cohort from the population of Åland. The prevalences of BV on the Åland Islands were: 15.6 %, 11.9 %, 8.7 %, and 8.6% in 1993, 1998, 2003, and 2008, respectively. This means that the prevalence of BV decreased between1993-2008 from 15.6% to 8.6%. The confidence intervals are not overlapping, thus indicating a significant decrease in prevalence from 1993 to 2008. The third study is a prospective, double-blind placebo controlled treatment study of BV. After conventional treatment with clindamycin, the patients were treated with adjuvant treatment of Lactobacilli-loaded tampons or placebo. The study showed no differences between the treatment and the placebo group, indicating that the tampon does not work at all. There are a variety of possible explanations for the result, which are analyzed in this thesis. The fourth study aimed to evaluate whether clindamycin is retained for a long time in the vaginal mucosa, thus disturbing the Lactobacilli in an attempt to reimplant Lactobacilli in the probiotic treatment studies. In conventional treatment, it is also useful to know whether clindamycin is retained, especially when considering the pressure from antibiotics on the antimicrobial sensitivity pattern. In the study, we found that the clindamycin disappears rapidly. Conclusion: BV research requires effort from many different scientific disciplines and the riddle of this condition and its treatment can only be resolved by concerted actions in research and treatment. The vision for the future includes, among other factors, better molecular biology based diagnostic tools, and knowledge of population based bacterial floras.
|
9 |
Avaliação da penetração de agentes antimicrobianos em biofilme de staphylococcus spp. e pseudomonas aeruginosa : considerações físico-químicas / Evaluation of the penetration of antimicrobial agents on biofilm of staphylococcus spp. and pseudomonas aeruginosa : physical-chemical considerationsPinto, Camille Catani Ferreira January 2011 (has links)
O advento do uso de cateteres venosos centrais na prática médica trouxe muitos benefícios aos pacientes, porém está relacionado a um aumento na incidência de infecções por microrganismos multirresistentes. Além disso, freqüentemente ocorre colonização por bactérias produtoras de biofilme. Estes microrganismos se aderem ao material abiótico desses dispositivos intravenosos, ficando protegidos sob a matriz exopolissacarídica do biofilme. Isso faz com que sistema imunológico e antimicrobianos sejam incapazes de ter sua ação plena e, muitas vezes, não atingem os microrganismos mais internos. O motivo deste insucesso é porque muitos desses agentes biológicos e farmacológicos apresentam propriedades físico-químicas incompatíveis com a penetração nesta matriz. Com o objetivo de determinar quais antimicrobianos são mais adequados para uso quando o microrganismo é produtor de biofilme e quais as propriedades físico-químicas que estão diretamente relacionadas à penetração do antimicrobiano na matriz polissacarídica, utilizou-se método colorimétrico com cristal violeta em microplacas modificado para obtenção de concentração inibitória mínima em biofilme (MBIC) e método já padronizado para concentração inibitória mínima (MIC). Para isso foram testados 10 antimicrobianos em Staphylococcus spp.: rifampicina, azitromicina, claritromicina, eritromicina, levofloxacino, gentamicina, doxiciclina, cloranfenicol, clindamicina e vancomicina. Para Pseudomonas aeruginosa foram testados os mesmos, exceto rifampicina e vancomicina. A discrepância entre MIC e MBIC foi muito grande para vários fármacos, mostrando a necessidade de se avaliar estes parâmetros antes do início da farmacoterapia para uma escolha correta, especialmente em hospitais. Os fármacos que apresentaram melhores resultados foram a rifampicina e os macrolídeos, enquanto que os menos efetivos foram vancomicina e clindamicina. Isso foi atribuído ao perfil lipofílico, porém com alguma solubilidade em água das melhores moléculas. Em contra ponto, a elevada área polar, complexidade e massa molar foram características negativas para a penetração em biofilme, resultando numa ineficácia para essas moléculas. Além disso, também foi avaliado o tratamento de polímeros plásticos com EDTA, obtendo-se redução significativa da produção de biofilme nas placas tratadas com o agente químico. / The use of central venous catheters in medicine has brought benefits to the patients and represents a great advance in clinical practice, while on the other hand this device is related to an increase in the incidence of infections caused by multiresistant pathogens. Furthermore, frequently, the catheters get colonized by biofilm producing bacteria. These microorganisms adhere to the abiotic material of the catheters keeping themselves protected underneath the exopolysaccharide matrix of biofilm, this way the immune system and antimicrobials are incapable to fulfill their action and, many times, are unable to reach internal bacteria. This fact is explained by the fact that many of the biological and pharmacological agents have physical-chemical properties incompatible with the penetration into the matrix. Aiming to determine which antimicrobials are suitable for using when dealing with a biofilm producing microorganism and which physical-chemical properties are directly related to the agent penetration into the polysaccharide matrix, we used colorimetric method with crystal violet to obtain biofilm minimum inhibitory concentration (MBIC) and the already standardized method for minimum inhibitory concentration (MIC). To accomplish these 10 antimicrobials were tested in Staphylococcus spp.: rifampin, azithromycin, clarithromycin, erythromycin, levofloxacin, gentamicin, doxycycline, chloramphenicol, clindamycin and vancomycin. For Pseudomonas aeruginosa all antimicrobials except for rifampin and vancomycin were included. There was a great difference between MIC and MBIC for many drugs, showing the need to evaluate these parameters before beginning treatment. The drugs with better results were rifampin and macrolides, while the worse were vancomycin and clindamycin, which can be attributed to the lipophilic profile with some water solubility present in the molecules with better results. The characteristics associated with poor penetration into biofilm were high polar surface area, complexity e molecular weight. Furthermore, the previous treatment of the plastic polymers with EDTA was accessed resulting in statistically significant reduction of biofilm production.
|
10 |
Avaliação da penetração de agentes antimicrobianos em biofilme de staphylococcus spp. e pseudomonas aeruginosa : considerações físico-químicas / Evaluation of the penetration of antimicrobial agents on biofilm of staphylococcus spp. and pseudomonas aeruginosa : physical-chemical considerationsPinto, Camille Catani Ferreira January 2011 (has links)
O advento do uso de cateteres venosos centrais na prática médica trouxe muitos benefícios aos pacientes, porém está relacionado a um aumento na incidência de infecções por microrganismos multirresistentes. Além disso, freqüentemente ocorre colonização por bactérias produtoras de biofilme. Estes microrganismos se aderem ao material abiótico desses dispositivos intravenosos, ficando protegidos sob a matriz exopolissacarídica do biofilme. Isso faz com que sistema imunológico e antimicrobianos sejam incapazes de ter sua ação plena e, muitas vezes, não atingem os microrganismos mais internos. O motivo deste insucesso é porque muitos desses agentes biológicos e farmacológicos apresentam propriedades físico-químicas incompatíveis com a penetração nesta matriz. Com o objetivo de determinar quais antimicrobianos são mais adequados para uso quando o microrganismo é produtor de biofilme e quais as propriedades físico-químicas que estão diretamente relacionadas à penetração do antimicrobiano na matriz polissacarídica, utilizou-se método colorimétrico com cristal violeta em microplacas modificado para obtenção de concentração inibitória mínima em biofilme (MBIC) e método já padronizado para concentração inibitória mínima (MIC). Para isso foram testados 10 antimicrobianos em Staphylococcus spp.: rifampicina, azitromicina, claritromicina, eritromicina, levofloxacino, gentamicina, doxiciclina, cloranfenicol, clindamicina e vancomicina. Para Pseudomonas aeruginosa foram testados os mesmos, exceto rifampicina e vancomicina. A discrepância entre MIC e MBIC foi muito grande para vários fármacos, mostrando a necessidade de se avaliar estes parâmetros antes do início da farmacoterapia para uma escolha correta, especialmente em hospitais. Os fármacos que apresentaram melhores resultados foram a rifampicina e os macrolídeos, enquanto que os menos efetivos foram vancomicina e clindamicina. Isso foi atribuído ao perfil lipofílico, porém com alguma solubilidade em água das melhores moléculas. Em contra ponto, a elevada área polar, complexidade e massa molar foram características negativas para a penetração em biofilme, resultando numa ineficácia para essas moléculas. Além disso, também foi avaliado o tratamento de polímeros plásticos com EDTA, obtendo-se redução significativa da produção de biofilme nas placas tratadas com o agente químico. / The use of central venous catheters in medicine has brought benefits to the patients and represents a great advance in clinical practice, while on the other hand this device is related to an increase in the incidence of infections caused by multiresistant pathogens. Furthermore, frequently, the catheters get colonized by biofilm producing bacteria. These microorganisms adhere to the abiotic material of the catheters keeping themselves protected underneath the exopolysaccharide matrix of biofilm, this way the immune system and antimicrobials are incapable to fulfill their action and, many times, are unable to reach internal bacteria. This fact is explained by the fact that many of the biological and pharmacological agents have physical-chemical properties incompatible with the penetration into the matrix. Aiming to determine which antimicrobials are suitable for using when dealing with a biofilm producing microorganism and which physical-chemical properties are directly related to the agent penetration into the polysaccharide matrix, we used colorimetric method with crystal violet to obtain biofilm minimum inhibitory concentration (MBIC) and the already standardized method for minimum inhibitory concentration (MIC). To accomplish these 10 antimicrobials were tested in Staphylococcus spp.: rifampin, azithromycin, clarithromycin, erythromycin, levofloxacin, gentamicin, doxycycline, chloramphenicol, clindamycin and vancomycin. For Pseudomonas aeruginosa all antimicrobials except for rifampin and vancomycin were included. There was a great difference between MIC and MBIC for many drugs, showing the need to evaluate these parameters before beginning treatment. The drugs with better results were rifampin and macrolides, while the worse were vancomycin and clindamycin, which can be attributed to the lipophilic profile with some water solubility present in the molecules with better results. The characteristics associated with poor penetration into biofilm were high polar surface area, complexity e molecular weight. Furthermore, the previous treatment of the plastic polymers with EDTA was accessed resulting in statistically significant reduction of biofilm production.
|
Page generated in 0.058 seconds